Sarepta Therapeutics (LTS:0L35) Marketable Securities: $189 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0L35 Sarepta Therapeutics Inc LTS:0L35
50 GF Score
Price $15.18
GF Value $132.41
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Marketable Securities?

Sarepta Therapeutics LTS:0L35 -1.11% 50 Marketable Securities is $189 Mil as of Mar. 2026. GuruFocus rates LTS:0L35 with a GF Score™ of 50/100 and a GF Value™ of $132.41 (Possible Value Trap). The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sarepta Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $189 Mil.

Sarepta Therapeutics's annual Marketable Securities declined from Dec. 2023 ($1,248 Mil) to Dec. 2024 ($252 Mil) and declined from Dec. 2024 ($252 Mil) to Dec. 2025 ($138 Mil).

Sarepta Therapeutics  (LTS:0L35) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sarepta Therapeutics Marketable Securities Related Terms

Sarepta Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Marketable Securities Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1,022.60 1,247.82 251.78 138.37

Sarepta Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 281.90 289.54 237.92 138.37 188.74
LTS:0L35
50GF Score
Sarepta Therapeutics Inc LTS:0L35
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $189 Mil mean?
Sarepta Therapeutics (LTS:0L35) has a Marketable Securities of $189 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Marketable Securities too high?
Sarepta Therapeutics' current Marketable Securities is $189 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Marketable Securities compare to MPLT and ZYME?
Sarepta Therapeutics' Marketable Securities of $189 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Marketable Securities is $189 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $132.41, compared to a current price of $15.18 — trading 88.5% below its estimated fair value. The current Marketable Securities is $189 Mil. Sarepta Therapeutics' overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Marketable Securities is $189 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of $15.18 is trading 88.5% below its estimated GF Value™ of $132.41. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0L35:

  • Marketable Securities: $189 Mil
  • GF Value™: $132.41 vs. price of $15.18 (88.5% below fair value)
  • GF Score™: 50/100 with 5 warning signs

No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
50GF Score

Get the complete analysis for LTS:0L35

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.18
Price
$132.41
GF Value